RT Journal Article
SR Electronic
T1 Automatic Detection of Target Engagement in Transcutaneous Cervical Vagal Nerve Stimulation for Traumatic Stress Triggers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.27.20018689
DO 10.1101/2020.01.27.20018689
A1 Gurel, Nil Z.
A1 Wittbrodt, Matthew T.
A1 Jung, Hewon
A1 Ladd, Stacy L.
A1 Shah, Amit J.
A1 Vaccarino, Viola
A1 Bremner, J. Douglas
A1 Inan, Omer T.
YR 2020
UL http://medrxiv.org/content/early/2020/03/16/2020.01.27.20018689.abstract
AB Transcutaneous cervical vagal nerve stimulation (tcVNS) devices are attractive alternatives to surgical implants, and can be applied for a number of conditions in ambulatory settings, including stress-related neuropsychiatric disorders. Transferring tcVNS technologies to at-home settings brings challenges associated with the assessment of therapy response. The ability to accurately detect whether tcVNS has been effectively delivered in a remote setting such as the home has never been investigated. We designed and conducted a study in which 12 human subjects received active tcVNS and 14 received sham stimulation in tandem with traumatic stress, and measured continuous cardiopulmonary signals including the electrocardiogram (ECG), photoplethysmogram (PPG), seismocardiogram (SCG), and respiratory effort (RSP). We extracted physiological parameters related to autonomic nervous system activity, and created a feature set from these parameters to: 1) detect active (vs. sham) tcVNS stimulation presence with machine learning methods, and 2) determine which sensing modalities and features provide the most salient markers of tcVNS-based changes in physiological signals. Heart rate (ECG), vasomotor activity (PPG), and pulse arrival time (ECG+PPG) provided sufficient information to determine target engagement (compared to sham) in addition to other combinations of sensors. resulting in 96% accuracy, precision, and recall with a receiver operator characteristics area of 0.96. Two commonly utilized sensing modalities (ECG and PPG) that are suitable for home use can provide useful information on therapy response for tcVNS. The methods presented herein could be deployed in wearable devices to quantify adherence for at-home use of tcVNS technologies.Competing Interest StatementDr. Bremner reported having funding support from ElectroCore LLC. Other authors reported no potential conflicts of interests.Clinical TrialNCT02992899Clinical Protocols https://www.brainstimjrnl.com/article/S1935-861X(19)30346-8/fulltext Funding StatementThis work was supported by the Defense Advanced Research Projects Agency (DARPA), Arlington, VA, under Cooperative Agreement N66001-16-2-4054. Dr. Shah is sponsored by the National Institutes of Health, Award K23 HL127251.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and MATLAB/Python codes, that support the findings of this study, are available from the corresponding author (Nil Gurel (nil{at}gatech.edu)) upon reasonable request.